Jasper Therapeutics (NASDAQ:JSPR) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report report published on Monday, Benzinga reports. HC Wainwright currently has a $65.00 price objective on the stock.

Other research analysts have also issued research reports about the stock. Stifel Nicolaus initiated coverage on shares of Jasper Therapeutics in a research note on Thursday, June 27th. They issued a buy rating and a $86.00 target price on the stock. BTIG Research initiated coverage on shares of Jasper Therapeutics in a research note on Monday, July 8th. They issued a buy rating and a $90.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Jasper Therapeutics in a research note on Tuesday, June 18th. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of Buy and a consensus price target of $69.56.

Jasper Therapeutics Trading Up 0.6 %

Shares of Jasper Therapeutics stock traded up $0.10 during mid-day trading on Monday, reaching $16.62. 141,445 shares of the stock were exchanged, compared to its average volume of 133,885. The company has a market cap of $250.36 million, a price-to-earnings ratio of -2.95 and a beta of 2.21. The firm has a 50-day simple moving average of $22.14 and a 200 day simple moving average of $21.97. Jasper Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.23. On average, research analysts predict that Jasper Therapeutics will post -4.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of JSPR. Rhumbline Advisers bought a new position in Jasper Therapeutics in the second quarter valued at approximately $300,000. Bank of New York Mellon Corp bought a new position in Jasper Therapeutics in the second quarter valued at approximately $740,000. Virtu Financial LLC bought a new position in Jasper Therapeutics in the first quarter valued at approximately $306,000. Ikarian Capital LLC acquired a new stake in shares of Jasper Therapeutics in the first quarter valued at approximately $3,088,000. Finally, StemPoint Capital LP acquired a new stake in shares of Jasper Therapeutics in the first quarter valued at approximately $3,794,000. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.